About Daniel Hetu, MD, MBA
Form D filings for Transposon Therapeutics from 2022 to 2024 list Daniel Hetu, MD, MBA as director.
Daniel Hetu, MD, MBA first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Daniel Hetu, MD, MBA in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Daniel Hetu, MD, MBA works with at each company, as listed on that company's latest Form D.
Transposon Therapeutics, Inc. · Form D, Jul 15, 2024
KK
Keith Katkin
Director
DP
Dennis Podlesak
Chief Executive Officer and director
LR
Lynne Rollins
Executive officer
EM
Eckard Weber, MD
Executive officer and director
BA
Brent Ahrens
Director
BM
Brian Slingsby, MD, PHD, MPH
Director
WM
William Harrington, MD, MBA
Director
JP
John Pacifico
Director